Lakefront Biotherapeutics (LKFT) Receivables - Other (2015 - 2025)

Lakefront Biotherapeutics (LKFT) has 11 years of Receivables - Other data on file, last reported at $4.5 million in Q4 2025.

• Receivables - Other for Q4 2025 came in at $4.5 million, up 84.1% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.5 million (up 84.1% YoY), and the FY2025 annual result was $4.5 million, up 84.1% from the prior year.
• Receivables - Other fell to $4.5 million in Q4 2025 per LKFT's latest filing, from $24.7 million in the prior quarter.
• Over five years, Receivables - Other peaked at $44.9 million in Q3 2024 and troughed at $2.4 million in Q4 2024.
• A 5-year average of $19.0 million and a median of $14.4 million in 2021 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other tumbled 56.67% in 2024, then soared 84.1% in 2025.
• A 5-year view of Receivables - Other shows it stood at $14.4 million in 2021, then tumbled by 44.25% to $8.0 million in 2022, then slumped by 30.41% to $5.6 million in 2023, then slumped by 56.67% to $2.4 million in 2024, then soared by 84.1% to $4.5 million in 2025.
• Business Quant data shows LKFT's Receivables - Other at $4.5 million in Q4 2025, $24.7 million in Q2 2025, and $22.9 million in Q1 2025.